Asymmetrex is Featured in Clinical Trials Arena Article

James Sherley, Director, Asymmetrex, talks to CTA to discuss a disruptive innovation that could change stem cell research

Previously in scientific research, there has been no way to count tissue stem cells, due to its difficulty. Experts over the years have lamented the lack of available technology, resigning themselves to not being able to resolve that problem.

But is that about to change?

James Sherley is the founder and director of Asymmetrex, an adult stem cell biotechnology start-up company. As the developer of AlphaSTEM Technology – a product that counts tissue stem cells – Sherley has been able to achieve a method that hasn’t been possible for 50 years.

In this compelling interview, Sherley sits down with CTA to explain how AlphaSTEM could mark a paradigmatic shift in stem cell and clinical research.

To read the rest of the article click here!

AsymmetrexAsymmetrex is Featured in Clinical Trials Arena Article

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *